正电子发射断层扫描/计算机断层扫描与乳腺癌。
PET/CT and breast cancer.
机构信息
St. Vincent's University Hospital, Dublin 4, Ireland.
出版信息
Cancer Imaging. 2010 Oct 4;10 Spec no A(1A):S59-62. doi: 10.1102/1470-7330.2010.9031.
Abstract
This paper summarises the current status of PET/CT in relation to breast cancer.
摘要
本文总结了 PET/CT 在乳腺癌方面的应用现状。
相似文献
1
PET/CT and breast cancer.
Cancer Imaging. 2010 Oct 4;10 Spec no A(1A):S59-62. doi: 10.1102/1470-7330.2010.9031.
2
Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
PLoS One. 2014 Dec 17;9(12):e115127. doi: 10.1371/journal.pone.0115127. eCollection 2014.
3
The evolving role of PET/CT in breast cancer.
Nucl Med Commun. 2010 Apr;31(4):271-3. doi: 10.1097/MNM.0b013e3283354cb4.
4
Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer.
Eur J Radiol. 2010 Feb;73(2):294-9. doi: 10.1016/j.ejrad.2008.10.031. Epub 2009 Feb 1.
5
Evaluation of ¹⁸F-FDG PET/MRI, ¹⁸F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer.
Eur J Radiol. 2016 Feb;85(2):459-65. doi: 10.1016/j.ejrad.2015.12.010. Epub 2015 Dec 19.
6
A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence.
Health Technol Assess. 2010 Oct;14(50):1-103. doi: 10.3310/hta14500.
7
FDG-PET and other imaging modalities for the evaluation of breast cancer recurrence and metastases: a meta-analysis.
J Cancer Res Clin Oncol. 2010 Jul;136(7):1007-22. doi: 10.1007/s00432-009-0746-6. Epub 2010 Jan 21.
8
Ovarian carcinoma metastasis to breast: role of PET/CT.
Isr Med Assoc J. 2013 Dec;15(12):784.
9
Breast cancer therapy: the role of PET-CT in decision making.
Q J Nucl Med Mol Imaging. 2009 Apr;53(2):210-23.
10
PET-CT imaging in the initial management of high-risk breast cancer patients: who did it help?
Breast J. 2009 Sep-Oct;15(5):554-6. doi: 10.1111/j.1524-4741.2009.00784.x. Epub 2009 Aug 4.
引用本文的文献
1
Untypical bilateral breast cancer with peritoneal fibrosis on F-FDG PET/CT: case report and literature review.
Front Med (Lausanne). 2024 Apr 29;11:1353822. doi: 10.3389/fmed.2024.1353822. eCollection 2024.
2
Overview of Artificial Intelligence in Breast Cancer Medical Imaging.
J Clin Med. 2023 Jan 4;12(2):419. doi: 10.3390/jcm12020419.
3
Ileal carcinoid tumor represents after prolonged remission as a solitary breast mass.
J Surg Case Rep. 2019 Jun 14;2019(6):rjz171. doi: 10.1093/jscr/rjz171. eCollection 2019 Jun.
4
Detection of distant metastases in patients with locally advanced breast cancer: role of F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging with computed tomography scans.
Radiol Bras. 2017 Jul-Aug;50(4):211-215. doi: 10.1590/0100-3984.2015-0232.
5
Prone Versus Supine Breast FDG-PET/CT for Assessing Locoregional Disease Distribution in Locally Advanced Breast Cancer.
Acad Radiol. 2015 Jul;22(7):853-9. doi: 10.1016/j.acra.2015.02.012. Epub 2015 Apr 10.
本文引用的文献
1
18F-FDG-PET/CT in patients with breast cancer and rising Ca 15-3 with negative conventional imaging: a multicentre study.
Eur J Radiol. 2011 Dec;80(3):828-33. doi: 10.1016/j.ejrad.2010.04.029. Epub 2010 May 23.
2
Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer.
J Clin Oncol. 2010 Jul 1;28(19):3154-9. doi: 10.1200/JCO.2009.27.5743. Epub 2010 Jun 1.
3
A meta-analysis of 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with breast cancer.
Skeletal Radiol. 2011 May;40(5):523-31. doi: 10.1007/s00256-010-0963-8. Epub 2010 May 22.
4
Role of fusion of prone FDG-PET and magnetic resonance imaging of the breasts in the evaluation of breast cancer.
Breast J. 2010 Jul-Aug;16(4):369-76. doi: 10.1111/j.1524-4741.2010.00927.x. Epub 2010 Apr 23.
5
The evolving role of PET/CT in breast cancer.
Nucl Med Commun. 2010 Apr;31(4):271-3. doi: 10.1097/MNM.0b013e3283354cb4.
6
Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging.
Eur J Nucl Med Mol Imaging. 2010 Jun;37(6):1077-86. doi: 10.1007/s00259-010-1399-z. Epub 2010 Mar 4.
7
Disease Restaging and Diagnosis of Recurrent and Metastatic Disease Following Primary Therapy with FDG-PET Imaging.
PET Clin. 2009 Jul 1;4(3):299-312. doi: 10.1016/j.cpet.2009.09.001.
8
Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches.
J Nucl Med. 2010 Mar;51(3):401-12. doi: 10.2967/jnumed.108.059584. Epub 2010 Feb 11.
9
Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients.
Eur J Nucl Med Mol Imaging. 2010 Jun;37(6):1069-76. doi: 10.1007/s00259-009-1343-2. Epub 2010 Feb 4.
10
FDG-PET and other imaging modalities for the evaluation of breast cancer recurrence and metastases: a meta-analysis.
J Cancer Res Clin Oncol. 2010 Jul;136(7):1007-22. doi: 10.1007/s00432-009-0746-6. Epub 2010 Jan 21.
Zotero 插件